Electroencephalographic characterization of brain dopaminergic stimulation by apomorphine in healthy volunteers

Neuropsychobiology

Volumn 39, Issue 1, 1999, Pages 49-56

  Luthringer, Rémy ^a,b   Rinaudo, Gilbert ^a,b   Toussaint, Michel ^b   Bailey, Paul ^a,b   Muller, Gérald ^b   Muzet, Alain ^c   Macher, Jean Paul ^a,b  

^a Centre Hospitalier de Rouffach   (France)

^b FORENAP   (France)

^c Ctr d'Etud de Physiol Appliquee   (France)

Author keywords

Apomorphine; Dopamine; Electroencephalography; Event related potentials; Frontal lobe; Mapping; Psychopharmacology

Indexed keywords

APOMORPHINE; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; NEUROLEPTIC AGENT;

ARTICLE; BETA RHYTHM; BRAIN MAPPING; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CROSSOVER PROCEDURE; DOPAMINERGIC ACTIVITY; DOUBLE BLIND PROCEDURE; DROWSINESS; ELECTROENCEPHALOGRAM; ELECTROPHYSIOLOGY; EVENT RELATED POTENTIAL; FRONTAL LOBE; HUMAN; HUMAN EXPERIMENT; LATENT PERIOD; MALE; NAUSEA; NEUROCHEMISTRY; NEUROENDOCRINOLOGY; NEUROTRANSMISSION; NORMAL HUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; VOMITING;

ADULT; APOMORPHINE; BRAIN MAPPING; CONTINGENT NEGATIVE VARIATION; CROSS-OVER STUDIES; DOPAMINE AGONISTS; DOUBLE-BLIND METHOD; ELECTROENCEPHALOGRAPHY; EVENT-RELATED POTENTIALS, P300; HEART RATE; HUMANS; MALE; REFERENCE VALUES; STIMULATION, CHEMICAL;

EID: 0032938585     PISSN: 0302282X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000026560     Document Type: Article

References (48)

1. Alexander GE, Crutcher MD: Functional architecture of basal ganglia circuits; Neural substrates of parallel processing. TINS 1990;13:266-271.
2. Anden NE, Rubenson A, Fuxe K, Hökfelt T: Evidence for dopamine receptor stimulation by apomorphine. J. Pharm Pharmacol 1967;19: 627-629.
3. Bean AJ, During MJ, Roth RH: Effects of dopamine autoreceptor stimulation on the release of colocalized transmitters: In vivo release of dopamine and neurotensin from rat frontal cortex. Neurosci Lett 1990;108:143-148.
4. Buchsbaum MS, Cappelletti J, Coppola R, Regal F, King AC, Van Kammen DP: New methods to determine the CNS effects of antigeriatric compounds: EEG topography and glucose use. Drug Dev Res 1982b;2:489-496.
5. Buchsbaum MS, Kessler R, King A, Johnson J, Cappelletti J: Simultaneous cerebral glucography with positron emission tomography and topographic electroencephalography; in Pfurtscheller G, Jonkman EJ, Lopes da Silva EH (eds): Brain Ischemia: Quantitative EEG and Imaging Techniques. Prog Brain Res. Amsterdam, Elsevier, 1984, vol 62.
6. Buchsbaum MS, Rigal F, Coppola R, Cappelletti, J. King AC, Johnson J: A new system for gray-level surface distribution maps of electrical activity. Electroencephalogr Clin Neurophysiol 1982a;53:237-242.
7. Carnoy P, Soubrie P, Puech AJ, Simon P: Performance deficit induced by low doses of dopamine agonists in rats: Towards a model for approaching the neurobiology of negative schizophrenic symptomatology? Biol Psychiatry 1986;21:11-22.
8. Cleghorn H, Szechtman H, Garnett ES, Nahmias C, Brown GM, Kaplan RD, Szechtman B, Franco S: Apomorphine effects on brain metabolism in neuroleptic-naive schizophrenic patients. Psychiatry Res Neuroimaging 1991; 40:135-153.
9. Cooley JW, Tuckey JW: An algorithm for the machine calculation of complex Fourier series. Math Comp 1965;19:297-301.
10. Dago KT, Luthringer R, Lengelle R, Rinaudo G, Macher JP: Statistical Decision Tree (SDT): A tool for studying pharmaco-EEG effects of CNS active drugs. Neuropsychobiology 1994; 29:91-96.
11. Di Chiara G, Porceddu ML, Vargiu L, Argiolas A, Gessa GC: Evidence for dopamine receptors mediating sedation in the mouse brain. Nature 1976;264:564-566.
12. Duchemin AM: La dopamine. Confrontations Psychiatr 1983;22:77-90.
13. Fink M, Itil TM, Shapiro D: Die Anwendung von Digital-Computer-Methoden in der Pharmakologie. Arzneimittelforschung (Drug Res) 1966; 16:297-299.
14. Fuxe K. Andersson K, Lofstrom A, Hokfelt T, Ferland L, Agnati LF, Perez de la Mora M, Schwarcz R, Eneroth P, Gustafsson JA, Skett P: Neurotransmitter mechanisms in the control of secretion of hormones from the anterior pituitary; in Fuxe K, Hokfelt T, Luft R (eds): Central Regulation of the Endocrine System New York, Plenum, 1979.
15. Galderisi S, Mucci A, Bucci P, Mignone ML, Maj M: Multilead quantitative EEG profile of clozapine in resting and vigilance-controlled conditions. Psychiatry Res Neuroimaging 1996; 67:113-122.
16. Gancher ST, Woodward WR, Boucher B, Nutt JG: Peripheral pharmacokinetics of apomorphine in humans. Ann Neurol 1989;26:232-238.
17. Grasby PM, Friston KJ, Bench CJ, Frith CD, Liddie PF, Frackowiak RS, Dolan RJ: The effect of dopamine agonist, apomorphine, on regional cerebral blood flow in normal volunteers. Psychol Med 1993;23:605-612.
18. Guenther W, Breitling D: Predominant sensorimotor area left hemisphere dysfunction in schizophrenia measured by brain electrical activity mapping. Biol Psychiatry 1985;20:515-532.
19. Herrmann WM: Development and critical evaluation of an objective procedure for the electroencephalographic classification of psychotropic drugs; in Hermann WH (eds): EEG in Drug Research. New York, Fischer, 1982.
20. Herrmann WM, Abt K, Coppola R, Etevenon P, Ferber G, Fink M, Gevins AS, Hinrichs H, Itil TM, John ER, Kubicki St, Künkel H, Kugler J, Lehmann D, Petsche H, Rappelsberger P, Röhmel J, Saito M, Saletu B, Scheuler W: International Pharmaco-EEG Group (IPEG): Recommendations for EEG and evoked potential mapping. Neuropsychobiology 1989;22:170-176.
21. Hjorth S, Engel JA, Carlsson A: Anticonflict effects of low doses of the dopamine agonist apomorphine in the rat. Pharmacol Biochem Behav 1986;24:237-240.
22. Ingvar DH, Sulg IA: Regional cerebral blood flow and EEG frequency content in man. Scand J Clin Invest 1969;23 (suppl 109): 47-66.
23. Jasper HH: The ten twenty electrode system of the International Federation. Electroencephalogr Clin Neurophysiol 1958;10:371-375.
24. Jezova D, Vigas M: Apomorphine injection stimulates beta-endorphin, adrenocorticotropin, and cortisol release in healthy man. Psychoneuroendocrinology 1988;13:479-485.
25. 2O PET study in humans. Neurosci Lett 1994;176:21-24.
26. Laduron P, Leysen JE: Domperidone, a specific in vitro dopamine antagonist, devoid of in vivo central dopaminergic activity. Biochem Pharmacol 1979;28:2161-2165.
27. Lal S: Apomorphine in the evaluation of dopaminergic function in man. Prog Neuropsychopharmacol Biol Psychiatry 1988;12:117-154.
28. Luthringer R, Dago KT, Patat A, Caille P, Curet O, Durieu G, Rinaudo G, Toussaint M, Granier LA, Macher JP: Pharmacoelectroencephalographic profile of befloxatone, a new reversible MAO-A inhibitor, in healty subjects. Neuropsychobiology 1996;34:98-105.
29. Luthringer R, Minot R, Toussaint M, Macher JP: Characterization of cortical dopaminergic stimulation using three-dimensional brain electrical activity mapping in healthy volunteers. Biol Psychiatry 1990;27:70.
30. McClelland GR, Cooper SM, Pilgrim AJ: A comparison of the central nervous system effects of haloperidol, chlorpromazine and sulpiride in normal volunteers. Br J Clin Pharmacol 1990; 30:795-803.
31. Macher JP, Luthringer R, Toussaint M, Minot R: Brain mapping and psychoactive drugs; in Hindmarch I, Stonier D (eds): Human Psychopharmacology: Measures and Methods. Wiley & Sons, Chichester, 1990, vol 3.
32. Matejcek M: Cortical correlates of vigilance regulation and their use in evaluating the effects of treatment. Adv Biochem Psychopharmacol 1980;23:339-348.
33. Nagata K, Tagawa K, Hiroi S, Nara M, Shishido F, Uemura K: Quantitative EEG and positron emission tomography in brain ischemia; in Pfurtscheller G, Lopes da Silva FH (eds): Functional Brain Imaging. Toronto, Huber, 1988.
34. Nicolle E, Pollak P, Serre-Debeauvais F, Richard P, Gervason CL, Broussolle E, Gavend M: Pharmacokinetics of apomorphine in parkinsonian patients. Fundam Clin Pharmacol 1993;7: 245-252.
35. Obrist WD, Sokolof L, Lassen NA, Lane MH, Butler RN, Feinberg I: Relation of EEG to cerebral blood flow and metabolism in old age. Electroencepalogr Clin Neurophysiol 1963;15:610-619.
36. Penit-Soria J, Andinat E, Crepel F: Excitation of rat prefrontal cortical neurons by dopamine: An in vitro electrophysiological study. Brain Res 1987;425:263-274.
37. Przedborski S, Levivier M, Raftopoulos C, Naini AB, Hildebrand J: Peripheral and central pharmacokinetics of apomorphine and its effects on dopamine metabolism in humans. Mov Disord 1995;10:28-36.
38. Randrup A, Braestrup C: Uptake of biogenic amines by newer antidepressant drugs: Relevance to the dopamine hypothesis of depression. Psychopharmacology 1977;53:309.
39. Roth RH: Dopamine autoreceptors: Pharmacology, function and comparison with postsynaptic dopamine receptors. Commun Psychopharmacol 1979;3:429-445.
40. Ruzicka E, Roth J, Spackova N, Mecir P, Jech R: Apomorphine induced cognitive changes in Parkinson's disease. J Neurol Neurosurg Psychiatry 1994;57:998-1001.
41. Shvaloff A: Effect of subcutaneous apomorphine on rat frontal cortex electroencephalogram. Neuropharmacology 1988;27:1313-1317.
42. Simon H, Scatton B, Le Moal M: Dopaminergic A10 neurones are involved in cognitive functions. Nature 1980;286:150-151.
43. Skirboll P, Grace AA, Bunney BS: Dopamine auto-and post-synaptic receptors: Electgrophysiological evidence for differential sensitivity to dopamine agonists. Science 1979;206:80-82.
44. Small JG, Milstein V, Small IV, Miller MJ, Kellams JJ, Corsaro CJ: Computerized EEG profiles of haloperidol, Chlorpromazine, clozapine and placebo in treatment resistant schizophrenia. Clin Electroencephalogr 1987;18:124-135.
45. Soufflet L, Toussaint M, Luthringer R, Koudou DT, Gresser J, Minot R, Macher JP: A statistical evaluation of the main interpolation methods applied to three dimensional EEG mapping. Electroencephalogr Clin Neurophysiol 1991;79:393-402.
46. Spiegel R, Aebi HJ: Method for recording subjective drug effects; in Kohlhammer W (ed): Psychopharmacology: An Introduction. Chichester, Wiley & Sons, 1983.
47. Tamminga CA, Schaeffer MH, Smith RC, Davis JM: Schizophrenic symptoms improve with apomorphine. Science 1978;200:576.
48. Yamamoto J: EEG power spectra and brain function; in Meyer EM, Simpkins JW, Yamamoto J (eds): Novel Approaches to the Treatment of Alzheimer's Disease. New York, Plenum, 1989.